Asbestos, a once popular refractory building material, is associated with a variety of illnesses such as mesothelioma and lung cancer. ACC is most often in the engineering and construction sector, targeting the treatment of people exposed to asbestos on the job.
Schmidt, who has more than 20 years of experience at ACC, said this has never been seen before and needs to be changed soon.
The ACC said it had a “constructive conversation” with Schmidt on this issue.
According to Schmidt, he was contacted by an insurance company that covers people with asbestos-related cancers, but the treatment was refused by ACC. In some cases he saw, ACC funding seemed to be denied because the drug wasn’t on the Drug Administration’s approval list.
However, even if a drug is not approved by the Drug Administration, ACC can fund the drug as long as it meets certain criteria such as cost-effectiveness.
In some cases, ACC did not consult with the patient’s treatment oncologist or look up notes, Schmidt said. Instead, it relied on documents such as letters that could lack a level of detail.
He said that if the drug is not fully aware of why it was prescribed, it may not be possible for the evaluator to fully determine whether to fund the drug, including a cost-effective assessment. Insisted.
“What that means is that ACC doesn’t have the correct clinical information needed to make that decision,” Schmidt said. “All they have to do is get a note from the person’s general practitioner. This note has a record of tumor treatment and sometimes an explanation from an oncologist.”
An ACC spokesperson said all claims would be evaluated on a case-by-case basis, including the extent to which clinical opinion was received in addition to the practitioner’s information.
“Mr. Schmidt will contact us directly, express our concerns and provide us with information about the incidents we need to investigate this. This is welcome and appropriate,” said a spokesman. Said.
Lawyers urge ACC to review asbestos cancer policy
Source link Lawyers urge ACC to review asbestos cancer policy